Loading
Diabetes Treatment and Management · Journal article
International Journal of Innovative Technologies in Social Science · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing current literature on mechanisms linking gut microbiota composition to pharmacological obesity treatment response, particularly GLP-1 receptor agonists. The review identifies potential pathways and proposes microbiota as a biomarker for precision medicine but does not present original data, controlled comparisons, or validated predictive models; it concludes that further prospective human studies are needed.
Narrative review. Individuals with obesity; no specific subpopulation or trial cohort defined..
Gut microbiota may influence obesity treatment efficacy through modulation of incretin secretion, bile acid metabolism, short-chain fatty acid production, gut barrier integrity, inflammatory pathways, and microbiota–gut–brain axis. GLP-1 receptor agonists may modify microbial composition, suggesting a bidirectional relationship between incretin signaling and microbiota regulation. Gut microbiota is identified as a promising therapeutic target and potential biomarker for precision obesity medicine.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize this as exploratory synthesis proposing microbiota-guided personalization of obesity pharmacotherapy; the evidence does not yet support microbiota profiling or modification as a standard clinical intervention. Implementation awaits prospective validation studies.
A narrative review synthesizing heterogeneous literature to raise mechanistic hypotheses about microbiota–treatment interactions, lacking original data, effect sizes, or a defined study population to support clinical claims.
As stated by the source record.
Clinicians should recognize this as exploratory synthesis proposing microbiota-guided personalization of obesity pharmacotherapy; the evidence does not yet support microbiota profiling or modification as a standard clinical intervention. Implementation awaits prospective validation studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is a chronic, multifactorial metabolic disease associated with significant morbidity, mortality, and increasing global prevalence. In recent years, the gut microbiota has emerged as an important regulator of host metabolism, energy homeostasis, inflammation, and appetite control (Gomes et al., 2018; Geng et al., 2022; Enache et al., 2024). At the same time, modern anti-obesity pharmacotherapy, particularly glucagon-like peptide-1 receptor agonists, has substantially improved therapeutic possibilities. However, considerable interindividual variability in treatment response remains a major clinical challenge. This narrative review aimed to summarize current evidence regarding the relationship between gut microbiota and pharmacological treatment response in obesity, with particular emphasis on GLP-1 receptor agonists and implications for personalized medicine. Scientific literature including review articles, experimental studies, observational studies, and clinical investigations concerning obesity pharmacotherapy and microbiota-related mechanisms was qualitatively synthesized. Current evidence suggests that gut microbiota may influence obesity treatment efficacy through modulation of incretin secretion, bile acid metabolism, short-chain fatty acid production, gut barrier integrity, inflammatory pathways, and the microbiota–gut–brain axis. GLP-1 receptor agonists may additionally modify microbial composition, suggesting a bidirectional relationship between incretin signaling and microbiota regulation (Gofron et al., 2025; Feng et al., 2024). Overall, gut microbiota represents a promising therapeutic target and potential biomarker for precision obesity medicine. Further prospective human studies are required to validate microbiota-guided approaches to obesity pharmacotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.